Published in MAbs on July 01, 2012
Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013. Leuk Lymphoma (2014) 0.86
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence. BioDrugs (2016) 0.82
Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence. BioDrugs (2017) 0.75
A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells. Oncotarget (2017) 0.75
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
The use of the avidin-biotin complex as a tool in molecular biology. Methods Biochem Anal (1980) 6.48
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem (1994) 5.51
An enzyme-release assay for natural cytotoxicity. J Immunol Methods (1983) 3.36
Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol (2007) 2.99
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol (2003) 2.62
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
The challenge of biosimilars. Ann Oncol (2007) 2.28
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood (1998) 2.17
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res (2006) 1.77
Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods (1992) 1.74
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood (2002) 1.66
Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis (2000) 1.55
Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother (2001) 1.51
CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry (1993) 1.46
Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem (2009) 1.31
Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol (2005) 1.20
An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood (2002) 1.17
Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng (2008) 1.12
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis (2003) 1.03
Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A (2003) 1.00
CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia (2002) 0.95
Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics (2003) 0.93
Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat (1999) 0.86
Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics (2003) 0.83
Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis (2006) 0.81
B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus (2004) 0.80
Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. Mol Immunol (2006) 0.79
[Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng (2007) 0.77
Stability of transfectomas producing chimeric antibody against the pre-S2 surface antigen of hepatitis B virus during a long-term culture. Biotechnol Bioeng (1995) 0.76
Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res (2009) 1.40
In vivo site-specific biotinylation of proteins within the secretory pathway using a single vector system. BMC Biotechnol (2008) 1.08
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology (2011) 0.97
Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics (2003) 0.93
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol (2009) 0.89
Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther (2012) 0.84
Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self-matter. Immunobiology (2005) 0.84
Chimeric anti-N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics (2003) 0.83
Gangliosides, Ab1 and Ab2 antibodies IV. Dominance of VH domain in the induction of anti-idiotypic antibodies by gene gun immunization. Mol Immunol (2007) 0.81
Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans. Arterioscler Thromb Vasc Biol (2012) 0.81
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs (2011) 0.80
Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells. Mol Immunol (2010) 0.80
Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner. Mol Immunol (2007) 0.79
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun (2008) 0.78
B7 and 34B7 monoclonal antibodies: a theoretical approach to the molecular basis of immunoglobulin cross-reactive antibodies. Hybridoma (Larchmt) (2007) 0.78
Construction of a recombinant non-mitogenic anti-human CD3 antibody. Hybridoma (Larchmt) (2010) 0.78
Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. Immunobiology (2006) 0.78
A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. Glycoconj J (2013) 0.77
Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study. Mol Immunol (2006) 0.76
Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. Mol Immunol (2011) 0.76
Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer (2014) 0.75
Immunopotentiating properties of a multispecific α-anti-idiotype antibody. MAbs (2012) 0.75
Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site. Mol Immunol (2011) 0.75